Procedural Pharmaceutical Lessons From Early Adopters

Experienced glaucoma surgeons share practical pearls on integrating sustained drug delivery into practice.

By: Christine Funke, MD, J. Morgan Micheletti, MD, FACS, Jason Bacharach, MD, Shivani S. Kamat, MD, Arkadiy Yadgarov, MD, Steven R. Sarkisian, Jr., MD, Robert F. Melendez, MD, MBA, Syril K. Dorairaj, MD, and, Pranav Vasu, MPH, Savak “Sev” Teymoorian, MD, MBA, Reza Alizadeh, MD, Lorraine M. Provencher, MD, Jai G. Parekh, MD, MBA, FAAO, Manjool Shah, MD, Inder Paul Singh, MD, Huda Sheheitli, MD, Reena A. Garg, MD, Zarmeena Vendal, MD

Glaucoma Physician September 1, 2026 Page(s): 16-20

Clinical Report: Procedural Pharmaceutical Lessons From Early Adopters

Overview

Experienced glaucoma surgeons provide insights on integrating sustained drug delivery systems into glaucoma management. Two FDA-approved options, Durysta and iDose TR, offer alternatives to daily topical therapies.

Background

Sustained-release drug delivery systems represent a significant advancement in glaucoma management, addressing challenges associated with daily topical medication adherence. Understanding how to effectively incorporate these options into clinical practice is essential for optimizing glaucoma care.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

Durysta and iDose TR are FDA-approved for reducing intraocular pressure in open-angle glaucoma.
Patient education on non-topical options can significantly influence treatment preferences.
Surgeons emphasize the importance of individualized treatment plans.
Effective communication about the benefits of sustained drug delivery can enhance patient acceptance.
Both implants provide a long-term solution for medication management.

Clinical Implications

Surgeons should consider sustained-release options as part of glaucoma management.

Conclusion

The integration of sustained drug delivery systems into glaucoma management emphasizes personalized care.